Supportive Care in Cancer

, Volume 24, Issue 11, pp 4471–4473

No man’s land: information needs and resources of men with metastatic castrate resistant prostate cancer


DOI: 10.1007/s00520-016-3358-0

Cite this article as:
Jenkins, V.A. & Fallowfield, L.J. Support Care Cancer (2016) 24: 4471. doi:10.1007/s00520-016-3358-0


The majority of men treated for prostate cancer will eventually develop castrate-resistant disease (CRPC) with metastases (mCRPC). There are several options for further treatment: chemotherapy, third-line hormone therapy, radium, immunotherapy, and palliation. Current ASCO guidelines for survivors of prostate cancer recommend that an individual’s information needs at all stages of disease are assessed and that patients are provided with or referred to the appropriate sources for information and support. Earlier reviews have highlighted the dearth of such services and we wished to see if the situation had improved more recently. Unfortunately, we conclude that there is still a lack of good-quality congruent information easily accessible specifically for men with mCRPC and insufficient data regarding the risks, harms, and benefits of different management plans. More research providing a clear evidence base about treatment consequences using patient reported outcome measures is required.


Metastatic castrate resistant prostate cancer Information needs Decision making Treatment 

Funding information

Funder NameGrant NumberFunding Note
Sanofi (UK)
  • G1580

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical SchoolUniversity of SussexBrightonUK

Personalised recommendations